[TNF alpha in the physiopathology of psoriasis].
Rozieres
A
A
INSERM U 503, IFR 128 et Immunologie Clinique et Allergologie, CH Lyon-Sud.
Hennino
A
A
Nicolas
J-F
JF
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018925:Chemokines / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D003879:Dermatologic Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D000068800:Etanercept; D005544:Forecasting; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D015603:Keratinocytes / Q000502:physiology; D008213:Lymphocyte Activation; D051379:Mice; D010641:Phenotype; D011565:Psoriasis / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000502:physiology; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000502:physiology; D012106:Research; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018925:Chemokines; D016207:Cytokines; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept